Generic drugmakers continue to face mounting pressure not only from pricing competition but also from Trump’s push for pharmaceutical import tariffs and the proposed “most-favored-nation” pricing ...

In light of the significant drop in Regeneron’s stock price, a natural question emerges: is REGN now a viable buying ...

Plans call for billionaire Elon Musk's commercial spaceflight company to bring Starship production and launch capabilities near Cape Canaveral, Florida. As SpaceX breaks ground in Florida on a new ...

But SpaceX won't attempt to return the Super Heavy booster to the launch pad to catch it with its "chopsticks." SpaceX's massive Starship launch vehicle, which is due to play a key role in future ...

Bayer announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending a label extension for Eylea 8 mg ...

Regeneron has faced setbacks in the regulatory approval process, as evidenced by the CRL received for the Eylea HD pre-filled syringe. These challenges could potentially delay the launch of new ...

Starship is the replacement hardware for the company’s existing Falcon 9 and Falcon Heavy rockets that launch from Florida and California. SpaceX has used its Texas site only for Starship test ...

Eylea, developed by Regeneron, is the world’s leading treatment for age-related macular degeneration, a common cause of blindness in older adults. Since its launch in 2013, Eylea has become a major ...

Bayer A.G. (OTCPK:BAYZF) (OTCPK:BAYRY) said that an advisory panel of the European Medicines Agency (EMA), endorsed the label expansion of a high-dose version of its ophthalmic drug, Eylea ...

A decision is anticipated in the coming weeks. If approved, Eylea 8 mg would become the only anti-VEGF therapy in the EU offering treatment intervals of up to six months for both nAMD and DME.